Join the Fight Against Tuberculosis at Upcoming TB Drug Accelerator Webinar

Bacterial infection. Rod-shaped bacteria, close-up view. 3D illustration
Tuberculosis (TB) remains one of the top-10 deadliest diseases globally. In its annual report, the World Health Organization states 10.4 million individuals were stricken with TB in 2016, resulting in 1.7 million deaths. Although seven countries account for 64% of all TB-related deaths, that does not mean it’s an isolated issue; TB is a worldwide problem.
Scientist.com is pleased to announce that the Tuberculosis Drug Accelerator (TBDA) program will be hosting a town hall-style webinar on December 13, 2017 to address the challenges in TB drug discovery. The webinar will be presented by Abbvie Distinguished Research Fellow Dr. Dale Kempf and Weill Cornell Medicine Associate Professor Ben Gold and moderated by the Bill & Melinda Gates Foundation Senior Program Officer Dr. Peter Warner. Some of the topics that will be addressed include TB’s short replication cycle and drug-resistant nature.
The TBDA was launched in 2012 as a partnership between major pharmaceutical companies and leading academic, non-profit and government researchers with the mission of developing new drug candidates that cure TB more quickly. To register for the webinar or get more information, click here. Help Scientist.com support the TBDA in their efforts to fight tuberculosis.
Sean Preci is currently Communications Director at Scientist.com, the world’s leading pharmaceutical marketplace for scientific services. He oversees all aspects of company-related communications and content.